Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
Abbott Laboratories logo
ABT
Abbott Laboratories
20:00:00
88.38 $
0.0000 (%0.00)
Previous Close: 88.5
Day Low₺87.76
Day High₺89.44
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

ABT: Abbott Laboratories Financials

Abbott Laboratories Income Statement

Total revenue
Net income
Gross margin TTM
55.51%
Operating margin TTM
18.16%
Net profit margin TTM
14.72%
Return on investment TTM
12.51%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue44,328,000,00041,950,000,00040,109,000,00043,653,000,000
Operating income8,048,000,0006,825,000,0006,435,000,0008,362,000,000
Net income6,524,000,00013,402,000,0005,723,000,0006,933,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue44,328,000,00041,950,000,00040,109,000,00043,653,000,000
Cost of revenue19,721,000,00020,625,000,00020,072,000,00021,330,000,000
Gross profit24,607,000,00021,325,000,00020,037,000,00022,323,000,000
Research and development expenses2,955,000,0002,823,000,0002,719,000,0002,852,000,000
General and administrative expenses12,378,000,000000
Selling and marketing expenses0000
Selling, general and administrative expenses12,378,000,00011,651,000,00010,883,000,00011,109,000,000
Other expenses1,253,000,000000
Operating expenses16,586,000,00014,474,000,00013,602,000,00013,961,000,000
Cost and expenses36,280,000,00035,099,000,00033,674,000,00035,291,000,000
Net interest income-111,000,000-259,000,000-313,000,000-132,000,000
Interest income230,000,000344,000,000385,000,000183,000,000
Interest expense341,000,000603,000,000698,000,000315,000,000
Depreciation and amortization2,746,000,0003,218,000,0003,243,000,0003,267,000,000
EBITDA11,553,000,00010,834,000,00010,605,000,00011,888,000,000
EBIT8,807,000,0007,616,000,0007,362,000,0008,621,000,000
Non-operating income (excl. interest)-759,000,000-765,000,000-927,000,000-259,000,000
Operating income8,048,000,0006,825,000,0006,435,000,0008,362,000,000
Total other income/expenses (net)418,000,000188,000,000229,000,000-56,000,000
Income before tax8,466,000,0007,013,000,0006,664,000,0008,306,000,000
Income tax expense1,942,000,000-6,389,000,000941,000,0001,373,000,000
Net income from continuing operations6,524,000,00013,402,000,0005,723,000,0006,933,000,000
Net income from discontinued operations0000
Other adjustments to net income0000
Net income6,524,000,00013,402,000,0005,723,000,0006,933,000,000
Net income deductions0000
Bottom line net income6,524,000,00013,402,000,0005,723,000,0006,933,000,000
EPS4834
Diluted EPS4834
Weighted average shares outstanding1,747,000,0001,731,698,0001,734,076,3581,753,000,000
Weighted average diluted shares outstanding1,747,000,0001,748,000,0001,749,000,0001,764,000,000

Abbott Laboratories Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
10,827,000,000%
Total debt / assets MRQ
—
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets86,713,000,00081,414,000,00073,214,000,00074,438,000,000
Total liabilities33,942,000,00033,513,000,00034,387,000,00037,533,000,000
Total equity52,130,000,00047,664,000,00038,603,000,00036,686,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents8,522,000,0007,616,000,0006,896,000,0009,882,000,000
Short-term investments417,000,000351,000,000383,000,000288,000,000
Cash and short-term investments8,939,000,0007,967,000,0007,279,000,00010,170,000,000
Net receivables7,929,000,0006,925,000,0006,565,000,0006,218,000,000
Accounts receivable7,929,000,0006,925,000,0006,565,000,0006,218,000,000
Other receivables0000
Inventory6,488,000,0006,194,000,0006,570,000,0006,173,000,000
Prepaid expenses0000
Other current assets2,640,000,0002,570,000,0002,256,000,0002,663,000,000
Total current assets25,996,000,00023,656,000,00022,670,000,00025,224,000,000
Property, plant and equipment (net)12,942,000,00011,733,000,00011,276,000,00010,278,000,000
Goodwill24,035,000,00023,108,000,00023,679,000,00022,799,000,000
Intangible assets5,526,000,0006,647,000,0008,815,000,00010,454,000,000
Goodwill and intangible assets29,561,000,00029,755,000,00032,494,000,00033,253,000,000
Long-term investments918,000,000886,000,000799,000,000766,000,000
Tax assets0000
Other non-current assets17,296,000,00015,384,000,0005,975,000,0004,917,000,000
Total non-current assets60,717,000,00057,758,000,00050,544,000,00049,214,000,000
Other assets0000
Total assets86,713,000,00081,414,000,00073,214,000,00074,438,000,000
Total payables5,906,000,0004,789,000,0004,787,000,0004,950,000,000
Accounts payable4,240,000,0004,195,000,0004,295,000,0004,607,000,000
Other payables1,666,000,000594,000,000492,000,000343,000,000
Accrued expenses1,745,000,0001,701,000,0001,597,000,0001,556,000,000
Short-term debt3,309,000,0001,754,000,0001,325,000,0002,481,000,000
Capital lease obligations (current)0000
Tax payables569,000,000594,000,000492,000,000343,000,000
Deferred revenue0000
Other current liabilities5,536,000,0005,913,000,0006,132,000,0006,502,000,000
Total current liabilities16,496,000,00014,157,000,00013,841,000,00015,489,000,000
Long-term debt10,827,000,00012,625,000,00013,599,000,00014,522,000,000
Capital lease obligations (non-current)931,000,000896,000,000949,000,000943,000,000
Deferred revenue (non-current)0000
Deferred tax liabilities (non-current)1,956,000,0001,372,000,0001,218,000,0001,841,000,000
Other non-current liabilities3,732,000,0004,463,000,0004,780,000,0004,738,000,000
Total non-current liabilities17,446,000,00019,356,000,00020,546,000,00022,044,000,000
Other liabilities0000
Capital lease obligations931,000,000896,000,000949,000,000943,000,000
Total liabilities33,942,000,00033,513,000,00034,387,000,00037,533,000,000
Treasury stock-17,177,000,000-16,844,000,000-15,981,000,000-15,229,000,000
Preferred stock0000
Common stock25,527,000,00025,153,000,00024,869,000,00024,709,000,000
Retained earnings49,781,000,00047,261,000,00037,554,000,00035,257,000,000
Additional paid-in capital0000
Accumulated other comprehensive income/loss-6,001,000,000-7,906,000,000-7,839,000,000-8,051,000,000
Other stockholders' equity0000
Total stockholders' equity52,130,000,00047,664,000,00038,603,000,00036,686,000,000
Total equity52,771,000,00047,901,000,00038,827,000,00036,905,000,000
Minority interest641,000,000237,000,000224,000,000219,000,000
Total liabilities and total equity86,713,000,00081,414,000,00073,214,000,00074,438,000,000
Total investments1,335,000,0001,237,000,0001,182,000,0001,054,000,000
Total debt15,067,000,00015,275,000,00015,873,000,00017,946,000,000
Net debt6,545,000,0007,659,000,0008,977,000,0008,064,000,000

Abbott Laboratories Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations9,566,000,0008,558,000,0007,261,000,0009,581,000,000
Cash from investing-2,422,000,000-2,338,000,000-3,133,000,000-1,740,000,000
Cash from financing-6,309,000,000-5,404,000,000-7,091,000,000-7,636,000,000
Net change in cash906,000,000720,000,000-2,986,000,00083,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income6,524,000,00013,402,000,0005,723,000,0006,933,000,000
Depreciation and amortization3,116,000,0003,218,000,0003,243,000,0003,267,000,000
Deferred income tax0000
Stock-based compensation664,000,000673,000,000644,000,000685,000,000
Change in working capital-803,000,000-9,217,000,000-2,475,000,000-1,519,000,000
Accounts receivable-652,000,000-691,000,000-356,000,000-68,000,000
Inventory195,000,000-58,000,000-232,000,000-1,413,000,000
Accounts payable954,000,000356,000,000-760,000,000420,000,000
Other working capital-1,300,000,000-8,824,000,000-1,127,000,000-458,000,000
Other non-cash items65,000,000482,000,000126,000,000215,000,000
Net cash from operating activities9,566,000,0008,558,000,0007,261,000,0009,581,000,000
Investments in property, plant and equipment-2,171,000,000-2,207,000,000-2,202,000,000-1,777,000,000
Acquisitions (net)-105,000,0001,000,000-837,000,00048,000,000
Purchases of investments-167,000,000-169,000,000-159,000,000-185,000,000
Sales/maturities of investments3,000,00028,000,00043,000,000152,000,000
Other investing activities18,000,0009,000,00022,000,00022,000,000
Net cash from investing activities-2,422,000,000-2,338,000,000-3,133,000,000-1,740,000,000
Net debt issuance-1,614,000,000-537,000,000-2,475,000,000-699,000,000
Long-term net debt issuance-1,499,000,000-437,000,000-2,496,000,000-746,000,000
Short-term net debt issuance-115,000,000-100,000,00021,000,00047,000,000
Net stock issuance-497,000,000-1,295,000,000-1,227,000,000-3,795,000,000
Net common stock issuance-497,000,000-1,295,000,000-1,227,000,000-3,795,000,000
Common stock issuance396,000,000000
Common stock repurchased-893,000,000-1,295,000,000-1,227,000,000-3,795,000,000
Net preferred stock issuance0000
Net dividends paid-4,116,000,000-3,836,000,000-3,556,000,000-3,309,000,000
Common dividends paid-4,116,000,000-3,836,000,000-3,556,000,000-3,309,000,000
Preferred dividends paid0000
Other financing activities-82,000,000264,000,000167,000,000167,000,000
Net cash from financing activities-6,309,000,000-5,404,000,000-7,091,000,000-7,636,000,000
Effect of FX changes on cash71,000,000-96,000,000-23,000,000-122,000,000
Net change in cash906,000,000720,000,000-2,986,000,00083,000,000
Cash at end of period8,522,000,0007,616,000,0006,896,000,0009,882,000,000
Cash at beginning of period7,616,000,0006,896,000,0009,882,000,0009,799,000,000
Operating cash flow9,566,000,0008,558,000,0007,261,000,0009,581,000,000
Capital expenditure-2,171,000,000-2,207,000,000-2,202,000,000-1,777,000,000
Free cash flow7,395,000,0006,351,000,0005,059,000,0007,804,000,000
Income taxes paid01,723,000,0001,475,000,0001,864,000,000
Interest paid0604,000,000662,000,000563,000,000